Navigation Links
Phase 2 Results for EntreMed's Panzem NCD Brain Cancer Study,Presented at ASCO

Safety and Single-Agent Activity Support Development of Panzem(R) NCD as a Combination Therapy for Glioblastoma Multiforme

ROCKVILLE, Md., June 05, 2007 /PRNewswire-FirstCall/ -- EntreMed, Inc. , a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announces the presentation of results of a single-agent Phase 2 study for Panzem(R) NCD (2ME2) in patients with glioblastoma multiforme (GBM). The data were presented by David A. Reardon, M.D., Associate Deputy Director at The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center and principal investigator for the study, at the American Society of Clinical Oncology (ASCO) Annual Meeting underway in Chicago.

The single-agent, open-label study, conducted at Duke University, was designed to assess the safety, pharmacokinetics and efficacy of Panzem(R) NCD in patients with recurrent GBM who have failed initial therapies. Of the 27 patients enrolled in this study, 78% had received two or more prior cancer agents. Results from this Phase 2 study included one partial response and seven stable diseases. Panzem(R) NCD was well-tolerated with reversible transaminase elevations as the only grade 3 toxicity in more than one patient, and no grade 4 toxicities.

Commenting on the results of the study, Dr. Reardon said, "Panzem(R) NCD was generally well-tolerated and showed modest activity as a single agent. This study and prior preclinical studies support the hypothesis that Panzem(R) NCD could be used in combination with an approved chemotherapeutic agent such as temozolomide (Temodar(R)) in GBM patients to potentially improve outcome further. The Duke University Brain Tumor Center has recently initiated a Phase 2 study of the Panzem(R) NCD/Temodar(R) combination."

Carolyn F. Sidor, M.D., MBA, EntreMed Vice President and Chief Medical Officer, commented, "Our clinical developme
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:7/30/2014)... 30, 2014 Research and Markets ... Chinese Aseptic Packaging Industry Report 2014" report to ... The Global and Chinese Aseptic Packaging Industry ... current state of the global Aseptic Packaging industry with ... provides a basic overview of the industry including definitions, ...
(Date:7/30/2014)... N.J. , July 30, 2014  InnoPharma, Inc. ... Injection, 10mg/vial (the generic equivalent of Zyprexa® injection), in ... agitation and disturbed behaviors in patients with schizophrenia or ... this generic injectable drug, InnoPharma has entered into an ... Sandoz Canada will make, use, sell, market and ...
(Date:7/30/2014)... YORK and KISSING, Germany ... and distributor of a single use and computer-assisted ("robotic") ... (Homi) Shamir , a worldwide recognized medical device executive, ... Mr. Shamir is a highly respected global ... recent assignment he served as President and Chief Executive ...
Breaking Medicine Technology:Global and Chinese Aseptic Packaging Industry Report 2014 2InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 3
... Okla., March 9, 2011 Sandra Smith filed suit today ... over a failed hip replacement system from Johnson & Johnson, ... market.  John David Hart of the Law Offices of John ... Ms. Smith. Smith, of Yukon, underwent surgeries ...
... Inc. (NYSE: WST ) today announced that management ... Miami, FL.  Management will present an overview of West,s business ... ET. A live audio webcast of the Company,s ... will be accessible from the Company,s website at www.westpharma.com/en/investors ...
Cached Medicine Technology:Woman Files Suit in Federal Court Against DePuy Orthopaedics, Inc.,/Johnson & Johnson Over Recalled Hip Device 2
(Date:7/30/2014)... 30, 2014 2014 Deep ... Industry” is a professional and in-depth research ... report provides basic Chitosan information, including Chitosan ... as well as industry overview. This research ... market as well as global industry analysis ...
(Date:7/30/2014)... -- For patients with asthma, just believing an odor ... for at least 24 hours, a new study indicates. ... what you think you smell," study author Cristina Jaen, ... said in a Monell news release. "Asthmatics ... expect that an odor is harmful, our bodies react ...
(Date:7/30/2014)... jockeying for supremacy within a cancerous tumor, the most ... fastest, researchers at Dana-Farber Cancer Institute report in a ... journal Nature . The findings have important ... the study authors explained: Doctors need to ascertain which ... metastasis and select drugs that target the critical genes ...
(Date:7/30/2014)... July 30, 2014 On July 29, ... the Indian Institute of Public Health, Gandhinagar released a ... India, Volume II: The Way Forward .” The report ... on Policies and Practices to Improve Nutrition Security in ... Father of the Green Revolution" and chair of the ...
(Date:7/30/2014)... Shabaikai is an ambitious historical novel, which ... Indians located on the shores of Russian River in ... ‘crooked snake’. Clarkson takes the reader into 20th Century ... prohibition and organized crime, providing a glimpse into the ... powerful men in the world convene the last two ...
Breaking Medicine News(10 mins):Health News:Chitosan Market & Sialic Acid Industry Research Analysis for World, China Regions Available at DeepResearchReports.com 2Health News:Chitosan Market & Sialic Acid Industry Research Analysis for World, China Regions Available at DeepResearchReports.com 3Health News:Chitosan Market & Sialic Acid Industry Research Analysis for World, China Regions Available at DeepResearchReports.com 4Health News:Even Thinking an Odor is Harmful May Spur Asthma Symptoms 2Health News:Target growth-driving cells within tumors, not fastest-proliferating cells 2Health News:Target growth-driving cells within tumors, not fastest-proliferating cells 3Health News:New Report on Integrated Health and Microfinance in India Shows the Way Forward 2Health News:New Report on Integrated Health and Microfinance in India Shows the Way Forward 3Health News:New Report on Integrated Health and Microfinance in India Shows the Way Forward 4Health News:Bill E. Clarkson Releases Debut Fact-Based Novel, Shabaikai 2
... The FDA has warned the consumer against the multiple ... issued after the FDA learned about the 24 related ... ,The FDA received information that counterfeit versions of ... web sites. Xenical manufactured by Hoffman-La Roche, Inc. help ...
... but new studies have revealed that coffee can be quite beneficial. ... cancers too. Some experts believe that it can also lower the ... ,Antioxidants in coffee help control the cell damage that can ... source of chlorogenic acid, which has been shown in animal experiments ...
... genes by American scientists has revealed a startling find. Around ... that is linked to// the risks of developing heart diseases. ... that is connected with diabetes. ,The findings, ... so many people have heart disease even if they do not ...
... countries met Friday to formally adopt a 24-page report on ... five days of heated debate to reaching a consensus on ... Friday," said Carloa Traverso Saibante, information officer for the UN ... IPCC report is formally adopted, it will be released to ...
... to mobilise US congressmen and senators against Indian authorities denying ... a case relating to his crusade against the corrupt healthcare ... of alleged wrongful treatment in India in May 1988, said: ... in US and will ask them to raise this issue ...
... Brazil government is up against giant drug manufacturers- Merck &Co. ... to the Brazilian government, there is no call to charge ... when Thailand is paying 65 cents for the same. ... last November. Last week the government declared the drug a ...
Cached Medicine News:Health News:New Health Drink—Coffe 2Health News:Gene Mutations Leave Caucasians Prone To Heart Diseases And Diabetes 2Health News:Climate Talks Reach Consensus in Bangkok 2Health News:NRI Threatens to Move US Congress for Justice in India 2Health News:Brazil Government In Contention With Merck Over Anti-AIDS Drug 2
... quality patient care., ,S/5 Anesthesia Delivery ... anesthesia delivery. As part of the S/5 ... electronically controlled gas delivery and agent vaporization ... create a truly integrated system. The S/5 ...
... filler and Tegagel hydrogel wound filler ... specially formulated to help provide a ... to enhance wound healing. The unique, ... for management of non-draining, minimally draining ...
... SS is a complete physician preference card ... management system for all the supply management ... preference card system combined with a broad ... entire case cart and operating suite supply ...
Easy to Use manual vacuum system features a pumping mechanism that can be operated with one hand....
Medicine Products: